Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2022 - 2025)

Zentalis Pharmaceuticals has reported Total Non-Current Liabilities over the past 4 years, most recently at $72.3 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $72.3 million for Q4 2025, down 21.71% from a year ago — trailing twelve months through Dec 2025 was $72.3 million (down 21.71% YoY), and the annual figure for FY2025 was $72.3 million, down 21.71%.
  • Total Non-Current Liabilities for Q4 2025 was $72.3 million at Zentalis Pharmaceuticals, down from $73.9 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ZNTL hit a ceiling of $112.5 million in Q4 2023 and a floor of $45.0 million in Q1 2022.
  • Median Total Non-Current Liabilities over the past 4 years was $96.4 million (2024), compared with a mean of $91.3 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 126.25% in 2023 and later dropped 28.98% in 2025.
  • Zentalis Pharmaceuticals' Total Non-Current Liabilities stood at $102.7 million in 2022, then increased by 9.6% to $112.5 million in 2023, then fell by 17.97% to $92.3 million in 2024, then dropped by 21.71% to $72.3 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $72.3 million (Q4 2025), $73.9 million (Q3 2025), and $76.7 million (Q2 2025) per Business Quant data.